Journal Article

Cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar compared with lenvatinib as the first-line treatment of unresectable or metastatic hepatocellular carcinoma

Wang, Zijing, Ma, Aixia, Li, Hongchao, Zhou, Ting, Yang, Lan, Wang, Xintian, Cao, Yingdan

2022

Overview

Background In recent years, programmed cell death protein-1 inhibitors, including sintilimab, have significantly prolonged the overall survival time of patients with unresectable or metastatic hepatocellular carcinoma (HCC); however, the cost-effectiveness of sintilimab is unclear. The aim of this study was to assess the cost-effectiveness of sintilimab plus bevacizumab biosimilar compared with lenvatinib as first-line treatment in patients with unresectable or metastatic HCC. Methods A lifetime partitioned survival model was developed to conduct a cost-effectiveness analysis of sintilimab plus bevacizumab biosimilar vs. lenvatinib for advanced HCC from a Chinese healthcare system perspective. The clinical and safety data were derived from two recent randomized clinical trials, the ORIENT-32 and REFLECT studies. Utility data were obtained from previous studies. Long-term direct medical costs and quality-adjusted life-years (QALYs) were predicted. Deterministic and probabilistic sensitivity analyses were performed to verify the robustness of the model. Results Compared with lenvatinib, combination therapy with sintilimab and bevacizumab biosimilar yielded an additional 0.493 QALYs at a higher cost ($33,102 vs. $21,037) (2021 US dollars). This resulted in a deterministic incremental cost-effectiveness ratio (ICER) of $24,462 per QALY in the base-case analysis. The ICERs were sensitive to the utility of post-progression and the cost of bevacizumab biosimilar. A lower ICER was estimated when the dose of bevacizumab biosimilar decreased from 15 mg to 7.5 mg per kilogram in the scenario analysis. In the probabilistic sensitivity analysis, the probability of being cost-effective for sintilimab treatment at willingness-to-pay (WTP) thresholds of one ($12,516) and three times the gross domestic product per capita in China ($37,547) were 11.6% and 88.6%, respectively. Conclusion Sintilimab plus bevacizumab biosimilar is likely to be a cost-effective treatment option as a first-line treatment for unresectable or metastatic HCC in China when WTP threshold is over $23,650.

• Publisher: BioMed Central,BioMed Central Ltd,Springer Nature B.V,BMC
• Subject: Apoptosis / Bevacizumab - therapeutic use / Biological products / Biosimilar Pharmaceuticals - therapeutic use / Cancer therapies / Carcinoma, Hepatocellular - drug therapy / Cell death / Clinical trials / Combination therapy / Cost analysis / Cost benefit analysis / Cost-effectiveness / Drug therapy / Forecasts and trends / GDP / Gross Domestic Product / Health Administration / Health Informatics / Health services / Hepatocellular carcinoma / Hepatoma / Humans / Hypertension / Kinases / Lenvatinib / Liver cancer / Liver Neoplasms - drug therapy / Medical economics / Medicine / Medicine & Public Health / Metastasis / Methods / Monoclonal antibodies / Nursing Research / Oncology / Patients / PD-1 / Proteins / Public Health / Sensitivity analysis / Sintilimab / Survival / Targeted cancer therapy